OBI Pharma, Inc. the OBI Pharma Board of Directors have appointed Heidi Wang, Ph.D. as Chief Executive Officer, a position previously held by Chairman and CEO, Yun Yen, MD. “We are excited that Dr. Wang has been appointed CEO of OBI Pharma to bring strategic vision and lead the organization with our innovative cancer therapeutics pipeline, towards successful development and potentially regulatory approvals worldwide. Dr. Wang brings a wealth of global executive management, scientific knowledge, development, and regulatory experience during her ~30 years tenure at Bristol Myers Squibb company (BMS).
“I am excited to contribute to the future direction and success of OBI Pharma as a potential leading cancer therapeutics biopharma company. I am impressed with the dedication and accomplishments of the organization to date. Additionally, with OBI’s innovative cancer pipeline under clinical trials to address unmet medical needs, it is an exciting time to join the organization,” stated Dr. Wang. Dr. Wang will report to Yun Yen, M.D, OBI Pharma’s Chairman of the Board.
Prior to joining OBI Pharma, she was Vice President, Head of Global Regulatory Sciences Oncology. Additionally, she has held executive and senior management roles of increasing responsibilities as Interim Head of R&D and Regulatory in China, US and International Regulatory Strategy, Global Product Labeling, Medical Communications, and Research Discovery. Dr. Wang has received the following degrees: Ph.D. and M.S. degrees at the University of Notre Dame (South Bend, IN) and B.S. degree at Fu-Jen University (Taipei, Taiwan). She also received postdoctoral training in cancer biology at The Cold Spring Harbor Laboratory (Cold Spring Harbor, NY). She has won numerous awards and authored numerous scientific publications during her career.
For trending Press Releases on the pharmaceutical industry, please visit:
KBI Biopharma appoints Jean-Baptiste Agnus as Chief Business Officer
